cyrilzakka/clinical-trials huggingface dataset:
Assessing the Impact of myHealth Rewards Enrollment Emails

The purpose of the study is to evaluate, prospectively, the potential impact of different email message conditions (no email, standard promotional email, social norms, and loss framing) on enrollment in a wellness program (myHealth Rewards) by Geisinger Health Plan (GHP) members.

The myHealth Rewards wellness program managed by GHP rewards those GHP members who carry their insurance through employment at Geisinger with reduced health insurance premiums over the course of the following year, if members register for the program and have their health measures on file by the enrollment deadline and are then able to meet their health goals by the respective due date. In spite of the potential savings to health plan members and the wellness program's potential to motivate engagement in healthy activities (with consequent improvement in health outcomes), over 20% of eligible GHP members have not yet enrolled in 2019, even after receiving promotional email communications and reminders. Therefore, the current study was developed to test whether different versions of emails are more effective than a standard reminder email or no-email condition in increasing myHealth Rewards login and enrollment rates. The standard email reminder mentions the average premium savings, the ease of the registration process, and the deadline for registering and having health measures on file, plus it provides links for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location. The social norms email notes that a majority (78%) of GHP members' colleagues had enrolled in 2018, it provides a testimonial from a medical director at Geisinger's Commonwealth School of Medicine, stating the ways in which myHealth Rewards helped that doctor personally, and it emphasizes the simplicity and ease of taking the first step toward enrollment. The loss framing email suggests that GHP members are currently "throwing away" a precise monetary amount in savings by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action. It is hypothesized that, on average, each of the emails will increase enrollment compared with no email. Among GHP members who never enrolled in the past, it is hypothesized that the standard email reminder will not be as effective as the social norms and loss framing emails. Therefore, email conditions will be compared separately among those who did and did not register in 2018. Findings will help inform how best to increase enrollment in a wellness program among health plan members who have already received past promotional communications and who may or may not have participated in the past.

Eligibility Criteria:
Inclusion Criteria:

* Geisinger employees who are benefits subscribers

Exclusion Criteria:

* Those who had already registered for myHealth Rewards in 2019, up through May 6, 2019
* New Geisinger employees hired between December 1, 2018 and May 6, 2019
* Existing Geisinger employees who transitioned from non-subscribers in 2018 to subscribers in 2019
Brain Markers of Suicide Risk and Psychological Pain in Elderly Depressed Patients

The main objective of this study is to show MRI functional and structural differences between depressed elderly patients with a history of attempted suicide compared to depressed elderly patients with no history of attempted suicide and to elderly subjects with no personal history of depression or attempted suicide (healthy controls).


Eligibility Criteria:
Inclusion Criteria:

* The patient must have given their free and informed consent and signed the consent form
* be a member or beneficiary of a health insurance plan
* aged 60 years-old or more
* must be right-handed
* with a diagnosis of a current major depressive episode of moderate to severe severity according to diagnostic criteria.
* with or without a personal history of attempted suicide during life
* hospitalized or followed by a consultant in the department of Psychiatry of Nîmes University Hospital or in the Sophoras private clinic

Exclusion Criteria:

* The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study
* under safeguard of justice
* refuses to sign the consent
* It is impossible to give the subject informed information
* Current psychotic symptoms.
* Bipolar disorder.
* The subject presents an acute somatic decompensation incompatible with the realization of this study.
* The patient presents a mental confusion or a known Mini Mental State Examination score \<24.
* Central neurological disease known in particular degenerative pathology, severe cranial trauma and severe cerebrovascular disease.
* Schizophrenia and other known psychotic disorders.
* Electroconvulsive therapy in the 12 months prior to study
* Inability to perform neuropsychological tests because of a language problem, poor understanding, a major tremor, inability to sit still, a major sight problem that cannot be corrected, or other severe cognitive impairment
* Contra-indication to magnetic resonance imaging (MRI): ferromagnetic implant in the body, piercing, claustrophobia, inability to remain elongated for 45 minutes.
Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus

The purpose of this study is to demonstrate that dutogliptin/PHX1149T is safe and tolerable.


Eligibility Criteria:
Inclusion Criteria:

* Completed Visit 7/Day 98 of the core protocol PHX1149-PROT202
* Current treatment of Type 2 diabetes mellitus in accordance with product labeling with metformin, or thiazolidinedione (TZD), or metformin + TZD

Exclusion Criteria:

* Inadequately controlled Type 2 diabetes mellitus with need for therapy with insulin
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

The purpose of this study is to evaluate the effect of BMS-919373 on atrial fibrillation (AF) through its effect on AF burden (AFB), or the percent of time in AF, in subjects with paroxysmal AF (pAF) when administered orally at a range of doses (2 mg once daily (QD), 5 mg QD, 12 mg QD following a 1-week period of loading doses of 3 mg QD, 8 mg QD and 20 mg QD, respectively) for a total of 4 weeks. It is hypothesized that treatment with BMS-919373 will reduce AF burden as compared to baseline relative to placebo.

Primary Purpose: Protocol designed to assess, by the use of long term non-invasive beat-to-beat monitoring with the SEEQ Mobile Cardiac Telemetry (MCT) system, the effect of BMS-919373 on the percent change from baseline relative to placebo of atrial fibrillation burden in subjects with paroxysmal atrial fibrillation.

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

* Signed informed consent
* Paroxysmal Atrial Fibrillation (pAF) with available documentation of AF and reporting symptoms within 6 months prior to screening
* Able to tolerate withdrawal of antiarrhythmic therapy (rhythm control)
* Echocardiographically measured left ventricular ejection fraction (LVEF) ≥40%,measured within 12 months of enrollment
* Echocardiographically measured left atrial (LA) diameter ≤ 5.0 cm, measured within 12 months of enrollment

Exclusion Criteria:

* Women of childbearing potential
* AFB \< 3% or \> 70%, during both screening periods independently
* Permanent or persistent Atrial Fibrillation
* Cardioversion within 3 months of study drug administration
* Stroke within 12 months of study drug administration
* TIA within 12 months of study drug administration
* Heart failure of NYHA class III or greater (symptoms of heart failure at rest or with minimal exertion)
* Heart failure of NYHA class II (symptoms of heart failure with routine levels of exertion)with ejection fraction \<40% as measured by echocardiography at any time within 12 months of study enrollment (i.e. additional ejection fraction measurements ≥ 40% over this period will not counter this exclusion)
* Valvular heart disease (including any valvular insufficiency or stenosis greater than"mild")
* Ablation within 3 months of study enrollment
The Study for the Reliability and Validity of Incremental Shuttle Walking Test for COPD Patients in Korea

Investigators will perform this study to validate shuttle walking tests in korean patients with chronic obstructive pulmonary disease. This study will be performed as multi-center prospective observational correlation study in ulsan university hospital and asan medical center. 36 participants will perform the exercise stress test with cycle, 6 minutes walking test and shuttle walking test. Investigators will analyze correlation 6 minutes walking test and shuttle walking test with exercise stress test.

Investigators will perform this study to validate shuttle walking tests in korean patients with chronic obstructive pulmonary disease. This study will be performed as multi-center prospective observational correlation study in ulsan university hospital and asan medical center.

18 patients will be enrolled in each hospital. When then visit, patients will perform questionnaire and laboratory study for baseline characteristics. After that, patients select memo, in which order for the exercise stress test with cycle, 6 minutes walking test and shuttle walking test will be written. Along that order, patients will perform each study at every two day in a week.

Investigators will analyze correlation 6 minutes walking test and shuttle walking test with exercise stress test. To analyze reliability in shuttle walking test, patients will shuttle walking test in two times. Researchers will analyze correlation between them.

Eligibility Criteria:
Inclusion Criteria:

* patients with respiratory symptom
* patients with forced expiratory volume 1/forced vital capacity \< 0.7 in pulmonary function test after bronchodilator
* patients with informed consent

Exclusion Criteria:

* history of unstable angina or myocardial infarction within 1 month
* more than 120/mins pulse rate in stable state
* uncontrolled arrhythmia or history of syncope
* Symptomatic aortic stenosis or severe cardiac valve stenosis
* acute pulmonary embolism, deep vein thrombosis, aortic dissection or pulmonary edema
* difficult condition for shuttle walking test; visual, auditory or psychological disturbance
* respiratory failure
* oxygen saturation ≤ 85% in stable state
* needs for oxygen supply during walking
* active infection, acute infective endocarditis, renal failure, hyperthyroidism or significant pulmonary hypertension
* Left main coronary artery stenosis, hypertrophic cardiomyopathy
* systolic blood pressure more than 180 mmHg
* diastolic blood pressure more than 100 mmHg
* pregnant women
* patients with orthopedic disease
Bioavailability, Pharmacokinetic and Mechanistic Study of Sinetrol® Xpur, a Polyphenol-rich Ingredient

The purpose of the study is to investigate the metabolization and the bioavailability of bioactive compounds from Sinetrol® Xpur, a polyphenol-rich ingredient, during a 16-week long chronical supplementation. It will be investigated the mechanism of action in adipocyte cells to try to explain the beneficial effects of the ingredient on body composition, especially on both abdominal subcutaneous and visceral fat mass.


Eligibility Criteria:
Inclusion Criteria:

1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Male and female with 30% min. and 70% max. of each sex, aged range: 20-50 years old
4. Overweight BMI range (27-30)
5. Having a total fat mass (BIA assessment) ≥ 25% for men and ≥ 32% for women
6. In good general health as evidenced by medical history
7. Ability to take oral medication and be willing to adhere to the regimen
8. Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration

Exclusion Criteria:

1. Metabolic/Chronic disorders or any kind of disease
2. Current use of any medication or food supplement
3. Have in the past been in long-term antibiotherapy (1 month or more) and/or a regular antiobiotherapy in the past 12 months
4. Former obese with a history of yoyo-effect
5. Have been involved in a weight loss program in the past 12 months or subjected to a weight reduction surgery
6. Pregnancy or lactation, or women wanting to have a baby
7. Menopausal women
8. Known allergic reactions to components of the supplement, i.e., orange, grapefruit, guarana and/or caffeine
9. Having started or quit smoking
10. Having a high alcohol consumption
Efficacy and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic Gastritis

To study the efficacy \& safety of Houtou Jianweiling tablet through the non-inferiority clinical trial of Houtou Jianweiling tablet with Omeprazole Enteric-coated tablet in patients with chronic non-atrophic gastritis.

This is a Randomized, Double-Blind, Placebo-Controlled, Non-inferiority Clinical Trial on the Efficacy and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic Gastritis.

Eligibility Criteria:
Inclusion Criteria:

* (1) Comply with the diagnostic criteria for chronic non-atrophic gastritis.
* (2) Age between 18 to 65 years.
* (3) Voluntarily participate the clinical trials and sign informed consent.

Exclusion Criteria:

* (1) Subjects with history of gastric surgery.
* (2) Patients with complicated and special types of gastritis, peptic ulcer, hemorrhage, cholecystitis, cholelithiasis, dysplasia of gastric mucosa or pathological diagnosis of suspected malignant change.
* (3) Patients with atrophy and/or intestinal metaplasia through pathological examination showed;.
* (4) Severe primary diseases associated with cardiovascular, cerebrovascular, lung, liver, kidney and hematopoietic system (above grade II of cardiac function; Cr value above the upper limit of normal value), or serious diseases affecting their survival, such as cancer or AIDS;
* (5) Patients who have used Chinese and Western medicine to treat chronic non-atrophic gastritis in the last two weeks;
* (6) Subjects with psychiatric disorders or a history of alcohol/drug abuse;
* (7) Pregnant women, woman who are preparing for pregnancy, lactating women;
* (8) Patients who are allergic constitution or allergic to known ingredients of test drugs;
* (9) Those who have participated in or are participating in other drug clinical trials in the past 3 months;
* (10) The syndrome differentiation is not clear or there are too many and complicated syndromes for the subjects;
* (11) Subjects that researchers do not consider appropriate to participate in clinical trials.
* (12) Patients with poor compliance are not allowed to participate in this trial.

  * Those who meet one or more of the above exclusion criteria cannot be included in the clinical trial.
Turkish Validity and Reliability of The Tampa Scale for Kinesiophobia for Temporomandibular Disorders

Objective: The aim of this study is to evaluate the validity and reliability of the Turkish version of the 'The Tampa Scale for Kinesiophobia for Temporomandibular Disorders (TSK-TMD)' questionnaire used to assess kinesiophobia in temporomandibular joint disorders.

Method: The "Tampa Kinesiophobia Scale in Temporomandibular Disorders" (TSK-TMD), which consists of 12 item, was adapted to Turkish with the translation and back-translation method. 111 patients (75 females, 36 males) who had been diagnosed with temporomandibular joint for at least 6 months and diagnosed as Temporomandibular Joint Disorder were participated to fill out the questionnaire. In the present study, participants were assessed with the Temporomandibular joint disorders evaluation form, Turkish TSK-TMD-12 item, Visuel Analogue Scale (VAS) and Pain Catastrophizing Scale (PCS). The internal consistency and test-retest reliability with a 3-5 days time were used to evaluate the reliability of the TSK-TMD. The reliability of the corelatıon was checked with PCS. Construct validity was assessed based on conﬁrmatory factor analysis (CFA).

We used Turkish TSK-TMD-12 item, Visuel Analogue Scale (VAS) and Pain Catastrophizing Scale (PCS) questionnaires in our study.

Eligibility Criteria:
Inclusion Criteria::

* volunteer participation in the study, between 18 and 65 years old,
* having symptoms for at least 6 months,
* being literate, and having communication to understand and answer questions.

Exclusion Criteria:

* toothache
* Cognitive impairment affecting their ability to understand and complete the study questionnaire
Nutritional Supplements on Blood Pressure 2008

Three different supplements will be used in the study (fruits and vegetable powders, whey protein and calcium) for patients with hypertension. The null hypothesis was that the supplements had no effects on participants' blood pressure.

Hypertensive participants will be randomly assigned into three groups. The first group of participants will take the fruits and vegetable powders mixed with water. The second group takes whey protein and the third group takes calcium pills. Blood pressure and heart rate variability will be measured every two weeks for three months.

Eligibility Criteria:
Inclusion Criteria:

* Age 20-70
* Hypertensive male and female subjects.

Exclusion Criteria:

* Severe cardiovascular and renal conditions.
* Pregnancies and taking medications.
Efficacy Study of Antiemetics to Reduce Postoperative Nausea and Vomiting

We randomized patients who received laparoscopic surgery for benign gynecologic disease into double dose (Experimental Group) or single dose (Control Group) of antiemetics. We compared the degree of postoperative nausea and vomiting in experimental and control groups.


Eligibility Criteria:
Inclusion Criteria:

* Laparoscopy for benign gynecologic disease

Exclusion Criteria:

* Vomiting within 24 hours before surgery
* Not using patient controlled analgesics postoperatively
Melatonin Treatment for Night-Eating Syndrome

This is an 8-week randomized, double-blind, placebo-controlled, parallel, fixed-dose pilot clinical trial to test the effectiveness of melatonin treatment versus placebo on symptoms of Night Eating Syndrome (NES). The investigators will also look at the effect of melatonin treatment on weight, metabolic parameters and sleep parameters in individuals with NES.

Night Eating Syndrome (NES) is a unique disorder characterized by a delayed pattern of food intake in which recurrent episodes of food consumption occurs after the evening meal and/or during nocturnal awakenings. Diagnostic criteria for NES include: (1) recurrent episodes of night eating, as manifested by eating after awakening from sleep or by excessive food consumption following the evening meal, (2) awareness of those eating episodes, and (3) significant distress or impairment caused by the disorder. Exclusion criteria are binge-eating disorder or another mental disorder, as well as medical disorders or medications that might better explain the disordered eating pattern. NES is also more common among patients with insomnia, eating disorders, and other psychiatric disorders. 100 participants with night eating syndrome will be recruited from the general population. They will be randomized to either a commercially available rapid-release formulation of melatonin (5 mg) or matching placebo capsules, that will be administered once a day for a total of 8 weeks. Participants will attend a screening appointment, a baseline assessment and additional research assessment visits every other week for the 8 weeks.

Eligibility Criteria:
Inclusion Criteria:

1. 18 - 65 years of age
2. English speaking
3. Meet DSM-V (Diagnostic and Statistical Manual - version 5) criteria for Night Eating Syndrome (NES)

Exclusion Criteria:

1. Unable to provide informed consent
2. Presence of alcohol/substance dependence
3. Presence of other eating disorders such as Binge Eating Disorder, Anorexia Nervosa.
4. Significant uncontrolled systemic illness (e.g. chronic renal failure, chronic liver disease, poorly controlled diabetes, poorly controlled congestive heart failure, chronic infectious disease, chronic autoimmune disease)
5. Women who are pregnant or breastfeeding
6. Allergy or hypersensitivity to melatonin
Retrospective Data Analysis PelviGYNious/EndoGYNious

The retrospective patient chart review aims to generate additional data to substantiate the safety and performance of EndoGYNious and PelviGYNious.


Eligibility Criteria:
Inclusion Criteria:

* Surgery for POP
* Implantation of either EndoGYNious or PelviGYNious
* Concomitant procedures are allowed
* Women minimum 18 years old
* Written informed consent for surgery

Exclusion Criteria:

Patients who rule out subsequent contact by the hospital will be excluded.

The use of the products is contraindicated in case of:

* pregnancy and/or patients who consider future pregnancies
* adolescent/ pubescent patients
* existence of a known sensitivity/ allergy against plastic materials such as polypropylene, polyester, etc.
* any pathology, including known or suspected uterine pathology, which would compromise placement of the implant/mesh (e.g. anatomical distortion or abnormalities)
* known anticoagulation disorder
* anticoagulant therapy
* autoimmune connective tissue disease
* renal insufficiency and upper urinary tract obstruction
* cancer illnesses of the vagina / cervix / rectum
* undergone radiation therapy on the vagina, cervix, rectum
* planned or emergency opening of the gastro-intestinal tract, as this could cause a risk of product contamination that could lead to infection that would require removal of the implant/device
* active or latent infection especially of the genital system and/or urinary tract
An Analysis of the Outcomes From Protocolized Perioperative Care for Patients Receiving Total Hip or Knee Arthroplasty

The care for patients receiving total hip and knee arthroplasty at the University of Arkansas for Medical Sciences has followed a structured care pathway since July 2015. This system of perioperative care has focused on preoperative assessment of medical co-morbidities and risks to postoperative functional recovery, anesthetic care focused on postoperative nausea and vomiting prevention and optimizing immediate postoperative functional ability, and aggressive postoperative physical therapy.

This is an observational study to look at the outcomes of this program at University of Arkansas for Medical Sciences. Areas of focus will be hospital length of stay, postoperative narcotic consumption, Visual Analog Scale scores, incidence of postoperative nausea and vomiting, and 30-day readmission rates, and health literacy rates.


Eligibility Criteria:
Inclusion Criteria:

- All men and women 18 years and older who underwent total hip arthroplasty or total knee arthroplasty surgery at UAMS between 7/01/2015 and 7/01/2016.

Exclusion Criteria:

- none